Preclinical investigations encompassing ethanol-induced gastric mucosal lesions, NSAID-mediated ulceration, cysteamine-induced duodenal injury, and inflammatory bowel disease analogues have reported associations between BPC157 exposure and reductions in mucosal lesion surface area, preservation of submucosal vascular architecture, and modulation of mucosal structural integrity
What is the Adaptation Program
BPC-157 No Tissue repair, anti-inflammatory action, angiogenesis Yes CJC-1295 with Ipamorelin Yes (indirect via GH and IGF-1) Stimulates natural growth hormone release Yes Sermorelin Yes (indirect via GH) GHRH analog that boosts natural GH production Yes AOD-9604 No (fat-focused) Supports fat metabolism while preserving lean mass Yes CJC-1295 and Ipamorelin: The Real Growth Pathway CJC-1295 paired with Ipamorelin is one of the most well-known peptide combinations for natural growth hormone support
04 Enhance Recovery and Performance May speed post-injury or post-workout recovery, helping maintain training consistency and physical resilience.
UK Regulatory Context: Research Use Only BPC-157 and TB-500 are not licensed medicines in the United Kingdom and are not approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for human use
